Skip to main content

CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC


People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.


Rituximab and COVID-19 vaccination: Timing may be key for antibody response


Findings from two studies suggest that among rituximab-treated patients, those with a longer time since their last infusion may be more likely to have an antibody response to vaccines against SARS-CoV-2.

Headlines from across medwireNews

19-01-2022 | Rheumatology | News | Article

Comorbidities may contribute to link between psoriatic arthritis and VTE risk

People with psoriatic arthritis have an increased risk for venous thromboembolism relative to the general population, and this association is likely to be related to underlying comorbidities, research suggests.

19-01-2022 | Diabetes | News | Article

Closed-loop benefits differ with high or low baseline HbA1c

Researchers find that the type of benefits people with type 1 diabetes gain from hybrid closed-loop insulin delivery differs according to their baseline glycemic control.

18-01-2022 | Diabetes | News | Article

Real-world data support HAPO link between LGA and raised maternal glycemia

Real-world data from Canada show that increasing maternal glycemia is associated with rising rates of large for gestational age births, confirming the results of the landmark HAPO trial.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

17-01-2022 | Rheumatology | News | Article

Weight gain during glucocorticoid use may signal treatment success in giant cell arteritis

Cumulative prednisone dose and effective disease control are both associated with increased BMI among patients with giant cell arteritis, post-hoc analysis of the GiACTA trial suggests.

17-01-2022 | Oncology | News | Article

BMI may be key to unlocking metformin NSCLC benefit

A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m2.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

Image Credits